key: cord-1015714-ivwh5bvk authors: Parent, Brendan; Caplan, Arthur; Mehta, Sapna A. title: Ethical considerations regarding COVID‐19 vaccination for transplant candidates and recipients date: 2021-07-19 journal: Clin Transplant DOI: 10.1111/ctr.14421 sha: 00229bb8be66e53f0372c9f623d0e9339dab938b doc_id: 1015714 cord_uid: ivwh5bvk Solid organ transplant (SOT) candidates and recipients were not included in the COVID‐19 vaccine trials that have justified vaccine administration to millions worldwide and will be critical to ending the pandemic. The risks of COVID‐19 for SOT candidates and recipients combined with data about this population's response to other vaccines has led to transplant centers recommending vaccination for their candidates and recipients in accordance with guidance from major transplant organizations. Relevant ethics considerations include: weighing the low risk of vaccination causing transplant complications against potentially limited antibody response of vaccines for transplant recipients; the equitable distribution of vaccines among vulnerable populations; the duty to steward and respect organs as limited resources; the duty to support vaccination; and patient autonomy. Vaccinated transplant patients and candidates should also consider participating in research studies to better understand the efficacy and potential long‐term risks in this patient population. There are difficult scenarios, like timing transplant after second vaccine dose, when to administer the second dose to a partially vaccinated candidate who gets an organ match, whether to vaccinate a recent transplant recipient with low exposure risk and which vaccine to use. Here we provide ethics considerations for vaccinating different groups within the transplant population. wileyonlinelibrary.com/journal/ctr 1 rejection. There has also been concern expressed that vaccines might contribute to organ rejection, though this has not been confirmed with prior vaccines. 3 However, the mRNA mechanism employed by two of the vaccines currently approved for emergency use is different from all other previously licensed vaccines, so it is difficult to make any strict inferences about mechanistic risks for these vaccines. The Johnson and Johnson vaccine uses a more traditional vaccine platform, and previously approved vaccines demonstrate very low risk of associated rejection episodes. 4 Johns Hopkins researchers recently published preliminary data from close to 200 transplant recipients suggesting the Pfizer and Moderna COVID-19 vaccines have not caused early signs of rejection and that the reactogenicity profile for this population is mild, similar to older adults. 5 The study also suggests that antibody response to vaccines is lower for this population, but this does not necessarily mean lack of benefit. Because both mRNA vaccines demonstrate significant protection in studied populations only 7 days after complete vaccination, it is likely that protection is conferred at least in part from cellular immunity regardless of humoral immunity. 6 This means it is critical to study antibody and cellular responses in transplant recipients further. Although there is reason to believe that transplant recipients might have impaired immune responses after vaccination, the risks of being vaccinated appear low and the risks of COVID-19 are, for many, high. death from COVID-19 than the general population, 10 and their com-promised immune systems might mean they are more likely to contract the virus. Data so far suggests low risk from actual vaccination for this population. 5 It is unclear how variants of concern impact vaccine efficacy in immunocompromised people; however, some vaccines confer significant protection against some variants for the general population. 11 While the degree of benefit conferred by a vaccine is not known and could be lower than for the general population, the likelihood of at least partial response, higher risk of severe disease, and risk of spreading SARS-CoV-2 variants strongly lean in favor of vaccination. From a deontological or duty-based approach, vaccinating transplant recipients and candidates will also contribute more information to the understanding of risks and benefits, which is critical, as long as this data can be systematically tracked. To the extent that vaccination ulations, but to date children and adolescents tend to be at lower risk for severe COVID-19. There are significant knowledge gaps regarding utility and safety for vaccines for other diseases in the pediatric transplant population. 13 These patients should only be offered vaccines approved for their age group, and further research should lead to pediatric COVID-19 vaccination guidelines. We must also consider how hard to urge vaccine-hesitant transplant candidates to proceed with vaccination. Part of prioritizing patient health is promoting patient trust. Vaccine-hesitant patients should be provided with sufficient information about vaccine safety and COVID-19 risk without force or judgment, and they should be allowed to make their own decisions. None. Brendan Parent drafted article. Sapna A. Mehta provided concept for article and critical revision. Arthur Caplan provided critical revision and approval of article. Brendan Parent receives salary support in the form of a gift from United Therapeutics. Data sharing is not applicable to this as no new data were created or analyzed in this study. Brendan Parent https://orcid.org/0000-0003-3057-5684 Response to hepatitis B vaccination in patients with liver cirrhosis Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation Impact of adjuvanted H1N1 vaccine on cell-mediated rejection in heart transplant recipients Does vaccination in solidorgan transplant recipients result in adverse immunologic sequelae? A systematic review and meta-analysis Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients COVID-19 vaccine FAQ sheet. American Society of Transplantation Guidance from the International Society of heart and lung transplantation regarding the SARS CoV-2 pandemic. The International Society of Heart and Lung Transplantation Transplant capacity in the COVID-19 era and early vaccine recommendations. American society of transplant surgeons COVID-19 in solid organ transplant recipients: initial report from the US epicenter Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies Effectiveness of influenza vaccine in patients on hemodialysis-a review Vaccines in pediatric transplant recipients-past, present, and future Ethical considerations regarding COVID-19 vaccination for transplant candidates and recipients